AnGes Inc

AnGes Inc has a market price of 53.0 JPY and a market cap of 21,005,718,960 JPY, with a price-to-book ratio of 6.83 and a price-to-tangible-book ratio of 6.83. The company's liquidity is characterized by a current ratio of 1.96 and a debt-to-equity ratio of 0.02, indicating a relatively strong liquidity position. However, the company's operating cash flow is negative at -5,750,366,000 JPY, and its free cash flow is also negative at -5,186,239,000 JPY. In terms of profitability, AnGes Inc has a return on equity of -1.6988 and a return on assets of -0.9667, both of which are below the industry median for the Biotechnology & Medical Research sector. The company's operating income is -5,140,225,000 JPY, and its net income is -5,225,754,000 JPY, indicating significant financial losses. The gross profit is 320,383,000 JPY, which is a small fraction of the company's total revenue of 874,120,000 JPY. AnGes Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. The company's capital expenditures are minimal at -14,322,000 JPY, suggesting limited investment in physical assets. The company's growth trajectory is constrained by its current financial performance, with a negative operating income and net income. The outlook for the current fiscal year and the next fiscal year is not provided in the available data, but the company's recent financial results suggest a challenging path to profitability. The company's liquidity and dilution risks are assessed as low, with no immediate filing-based liquidity or dilution flags detected. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's financial snapshot and valuation metrics suggest that it is in a development phase with high R&D expenditures and limited revenue generation.